Medical articles today

/* 728x15, */

ZOLL LL Receives FDA Approval To Market New LifeVest Model

ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, has received approval from the U.S. Food and Drug Administration (FDA) to market and sell a new model of the LifeVest® wearable defibrillator. The LifeVest wearable defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), allowing their physicians time to assess their long-term arrhythmic risk and make appropriate plans, including potentially the decision to implant a cardioverter defibrillator (ICD). The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA.

TAU Grows New Blood Vessels To Combat Heart Disease

Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart - eliminating the need for risky surgery altogether. In heart disease, blood vessels are either clogged or die off, starving the heart of oxygen and leaving it highly susceptible to a cardiac attack. Dr. Hardy and her research partner Prof. Alexander Battler have developed a protein-based injection that, delivered straight to muscles in the body, sparks the regrowth of tiny blood vessels.

/* 468x60, */

Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System

Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system. The study is a double-blind, randomized, placebo-controlled, single ascending dose study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of RB006 administered subcutaneously, with and without intravenously administered RB007, in healthy adult volunteers. REG1 is a two component system composed of RB006, a specific and direct inhibitor of Factor IXa, and RB007, the specific controlling agent that reverses RB006.

Cardiac Muscle Patch Succeeds In Animals

Scientists in Israel have successfully grown heart muscle in the abdomen and then used it to patch and repair the hearts of rats after they had suffered heart attack. This is the first study to show it is possible to improve the health of a heart after it has been damaged through heart attack. The experiment was conducted by lead author Dr Tal Dvir, of the Department of Biotechnology Engineering at Ben-Gurion University of the Negev in Beer-Sheva, Israel and colleagues, and appears in the 24 August online issue of the Proceedings of the National Academy of Sciences, PNAS. The authors wrote that recent progress in bioengineering of cardiac patches has raised the possibility of regenerating heart muscle after it has been damaged through heart attack.

Americans Urged To Eat Less Added Sugar

New guidelines from the American Heart Association (AHA) urge Americans to cut their added sugar intake because there is evidence that high intake of added sugars is implicated in a number of poor health conditions such as obesity, high blood pressure and risk factors for heart disease and stroke. The new guidelines appear in a scientific statement by lead author Dr Rachel K Johnson, associate provost and professor of nutrition at the University of Vermont in Burlington, and colleagues on behalf of the AHA's Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism and the Council on Epidemiology and Prevention and are published in the 24 August issue of Circulation, the journal of the American Heart Association.

/* 468x60, */

Cytokinetics To Present Phase IIa Clinical Trials Data On Omecamtiv Mecarbil At The European Society Of Cardiology Congress 2009

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data relating to two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic cardiomyopathy and angina, are scheduled to be presented in two poster presentations at the European Society of Cardiology Congress 2009, to be held August 29 - September 2, 2009 at the Fira Gran Via Plaza Europa in Barcelona, Spain. Poster Presentations Abstract #84776: "Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452" is scheduled to be displayed on Monday, August 31, 2009 from 8:30 AM - 12:30 PM Central European Summer Time (CEST) in Zone 3.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy